Join Growin Stock Community!

Telomir pharmaceuticals, inc. common stockTELO.US Overview

US StockHealthcare
(No presentation for TELO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TELO AI Insights

TELO Overall Performance

TELO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TELO Recent Performance

-2.76%

Telomir pharmaceuticals, inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

TELO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TELO Key Information

TELO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TELO Profile

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Price of TELO

TELO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TELO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.55
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.55
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is TELO's latest earnings report released?

    The most recent financial report for Telomir pharmaceuticals, inc. common stock (TELO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TELO's short-term business performance and financial health. For the latest updates on TELO's earnings releases, visit this page regularly.

  • How much cash does TELO have?

    At the end of the period, Telomir pharmaceuticals, inc. common stock (TELO) held Total Cash and Cash Equivalents of 7.33M, accounting for 0.99 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TELO's EPS continuing to grow?

    According to the past four quarterly reports, Telomir pharmaceuticals, inc. common stock (TELO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TELO?

    Telomir pharmaceuticals, inc. common stock (TELO)'s Free Cash Flow (FCF) for the period is -927.26K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 7.49% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TELO?

    The latest valuation data shows Telomir pharmaceuticals, inc. common stock (TELO) has a Price-To-Earnings (PE) ratio of -4.19 and a Price/Earnings-To-Growth (PEG) ratio of 0.12. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.